Compare MPB & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPB | SPRY |
|---|---|---|
| Founded | 1868 | 2015 |
| Country | United States | United States |
| Employees | N/A | 159 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.0M | 788.5M |
| IPO Year | 1996 | 2020 |
| Metric | MPB | SPRY |
|---|---|---|
| Price | $32.45 | $8.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $37.00 | ★ $40.00 |
| AVG Volume (30 Days) | 106.5K | ★ 1.7M |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $30.95 | $87.40 |
| Revenue Next Year | $9.45 | $81.64 |
| P/E Ratio | $90.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.83 | $6.66 |
| 52 Week High | $35.22 | $18.63 |
| Indicator | MPB | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 49.40 |
| Support Level | $30.66 | $7.82 |
| Resistance Level | $34.88 | $8.61 |
| Average True Range (ATR) | 0.80 | 0.55 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 50.90 | 42.91 |
Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.